吸入式一氧化氮市场规模、份额、成长分析（按类型、产品类型、应用、浓度、产品、最终用户和地区划分）—产业预测（2026-2033年）

全球吸入式一氧化氮市场规模预计在 2024 年达到 12.9 亿美元，从 2025 年的 14 亿美元成长到 2033 年的 25.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 7.9%。

除了对呼吸系统和心血管健康的益处外，一氧化氮还具有显着的抗菌特性，并在维持多重器官存活和血管稳态方面发挥关键作用。吸入一氧化氮可透过扩张肺动脉来改善通气/灌注比，促进动脉氧合，进而增加流向通气良好肺部区域的血流。由于一氧化氮能够改善血液循环、氧气输送和营养吸收，最终提高运动表现，因此在运动员中得到广泛应用。主要产业参与者正密切关注医药和医疗分销领域，并致力于开发关键气体的管道连接。由于终端用户需求不断增长、人们对一氧化氮医疗应用的认识不断提高、心血管和呼吸系统疾病患病率上升以及研发领域的进步，全球吸入一氧化氮市场预计将迎来显着增长。

全球吸入式一氧化氮市场驱动因素

全球吸入式一氧化氮市场的主要驱动力是呼吸系统疾病发生率的不断上升。由于呼吸系统疾病持续影响全球相当大比例的人口，预计吸入式一氧化氮作为治疗选择的需求将会增加。空气污染、烟草烟雾以及各种职业风险因素等环境因素会显着损害呼吸系统健康，并增加此类疾病的可能性。此外，人口老化导致免疫反应减弱和肺功能自然衰退，使个体更容易患上呼吸系统疾病。这一趋势表明，全球呼吸系统相关健康问题将持续增加。

限制全球吸入式一氧化氮市场的因素

由于监管方面的严格挑战，全球吸入式一氧化氮市场面临多重限制。製造商在产品核可前必须遵守众多监管标准，这既耗时又昂贵，往往会延缓新治疗方法的研发和上市。此外，不同医疗体系在定价和报销方面的复杂性也构成了额外的障碍。企业必须与支付者进行复杂的谈判以确保吸入式一氧化氮的报销，同时也要参与卫生技术评估（HTA）。这使得新参与企业难以有效地应对激烈的竞争。

全球吸入式一氧化氮市场趋势

全球吸入式一氧化氮市场正处于强劲增长期，其主要驱动力是气喘和慢性阻塞性肺病（COPD）等呼吸系统疾病的日益流行，这些疾病严重影响患者的生活品质。吸烟率的上升和工业污染的加剧进一步恶化了这些疾病的症状，导致这些慢性疾病的发生率上升。因此，由于吸入式一氧化氮在治疗严重呼吸窘迫方面具有疗效，因此人们对包括吸入式一氧化氮在内的有效治疗方法的需求日益增长。随着人们对吸入式一氧化氮在治疗急慢性呼吸道疾病方面的益处认识不断提高，该市场有望大幅扩张，以满足受影响人口的迫切医疗需求。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球吸入式一氧化氮市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 儿童
• 成人版

全球吸入式一氧化氮市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 吸入式一氧化氮输送系统
• 消耗品
• 一氧化氮钢瓶
• 计量配件
• 其他的

全球吸入式一氧化氮市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 新生儿呼吸护理
• 慢性阻塞性肺病（COPD）
• 急性呼吸窘迫症候群（ARDS）
• 结核病治疗
• 疟疾治疗
• 其他的

全球吸入式一氧化氮市场规模（按浓度和复合年增长率划分）（2026-2033 年）

• 100 ppm
• 800 ppm
• 其他的

全球吸入式一氧化氮市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 一次性
• 系统

全球吸入式一氧化氮市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 门诊治疗中心
• 诊所

全球吸入式一氧化氮市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Mallinckrodt Pharmaceuticals（United States）
• Key Developments
• Air Liquide Healthcare（France）
• VERO Biotech（United States）
• Getinge AB（Sweden）
• Beyond Air, Inc.（United States）
• SLE Ltd.（United Kingdom）
• Bellerophon Therapeutics（United States）
• International Biomedical（United States）
• NIOX Group plc（United Kingdom）
• BOC Healthcare（United Kingdom）
• Merck KGaA（Germany）
• Nu-Med Plus Inc.（United States）
• Perma Pure LLC（United States）
• HALMA PLC（United Kingdom）
• Matheson Tri-Gas Inc.（United States）
• Circassia Pharmaceuticals（United Kingdom）
• International Biomedical（United States）

结论与建议

Global Inhaled Nitric Oxide Market size was valued at USD 1.29 Billion in 2024 and is poised to grow from USD 1.4 Billion in 2025 to USD 2.57 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

Nitric oxide plays a vital role in supporting multiorgan survival and vascular homeostasis, with notable antibacterial properties alongside its benefits for respiratory and cardiovascular health. Inhaled nitric oxide enhances ventilation-perfusion matching and increases arterial oxygenation by dilating pulmonary arteries, thereby boosting blood flow to well-ventilated lung regions. Its use is popular among athletes for improving blood circulation, oxygen delivery, and nutrient absorption, ultimately enhancing exercise performance. Key industry players are focused on developing pipeline connections for essential gases, while monitoring distribution in the pharmaceutical and healthcare sectors. The global inhaled nitric oxide market is poised for significant growth, driven by increasing end-user demand, rising awareness of its healthcare applications, escalating rates of cardiovascular and respiratory conditions, and ongoing advancements in research and technology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Inhaled Nitric Oxide market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Inhaled Nitric Oxide Market Segments Analysis

Global Inhaled Nitric Oxide Market is segmented by Type, Product Type, Application, Strength, Product, End-user and region. Based on Type, the market is segmented into Pediatric and Adult. Based on Product Type, the market is segmented into Inhaled Nitric Oxide Delivery Systems, Consumables, Nitric Oxide Cylinders, Delivery Accessories and Others. Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), Tuberculosis Treatment, Malaria Treatment and Others. Based on Strength, the market is segmented into 100 ppm, 800 ppm and Others. Based on Product, the market is segmented into Disposables and System. Based on End-user, the market is segmented into Hospitals, Ambulatory Centers and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Inhaled Nitric Oxide Market

The Global Inhaled Nitric Oxide market is primarily propelled by the growing incidence of respiratory diseases. As respiratory disorders continue to affect a significant portion of the global population, the demand for inhaled nitric oxide as a therapeutic alternative is expected to rise. Environmental factors such as air pollution, tobacco smoke, and various occupational hazards contribute significantly to diminishing respiratory health, thus increasing the likelihood of developing such conditions. Additionally, the aging demographic, characterized by declining immune responses and natural alterations in lung function, renders individuals more susceptible to respiratory ailments. This trend suggests a continual rise in respiratory-related health issues worldwide.

Restraints in the Global Inhaled Nitric Oxide Market

The Global Inhaled Nitric Oxide market faces several constraints due to stringent regulatory challenges. Manufacturers are obligated to comply with numerous regulatory standards before their products can be approved, which is both costly and time-intensive. This often results in delays in the development and launch of new treatments. Additionally, the complexities surrounding pricing and reimbursement across various healthcare systems create further hurdles. Companies must engage in intricate negotiations with payers to secure reimbursement for inhaled nitric oxide while also grappling with health technology assessments, making it difficult for new entrants to navigate the competitive landscape effectively.

Market Trends of the Global Inhaled Nitric Oxide Market

The Global Inhaled Nitric Oxide market is seeing a robust growth trajectory, driven largely by the rising prevalence of respiratory illnesses such as asthma and COPD, which significantly impair quality of life. The escalation in smoking rates and industrial pollution is further exacerbating symptoms and increasing the incidence of these chronic conditions. Consequently, there is a heightened demand for effective treatments, including inhaled nitric oxide, due to its therapeutic benefits in managing severe respiratory distress. As awareness grows regarding the advantages of inhaled nitric oxide in acute and chronic respiratory scenarios, the market is poised for substantial expansion, catering to the pressing healthcare needs of affected populations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Inhaled Nitric Oxide Market Size by Type & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Inhaled Nitric Oxide Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Inhaled Nitric Oxide Delivery Systems
• Consumables
• Nitric Oxide Cylinders
• Delivery Accessories
• Others

Global Inhaled Nitric Oxide Market Size by Application & CAGR (2026-2033)

• Market Overview
• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Tuberculosis Treatment
• Malaria Treatment
• Others

Global Inhaled Nitric Oxide Market Size by Strength & CAGR (2026-2033)

• Market Overview
• 100 ppm
• 800 ppm
• Others

Global Inhaled Nitric Oxide Market Size by Product & CAGR (2026-2033)

• Market Overview
• Disposables
• System

Global Inhaled Nitric Oxide Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Centers
• Clinics

Global Inhaled Nitric Oxide Market Size & CAGR (2026-2033)

• North America (Type, Product Type, Application, Strength, Product, End-user)
  • US
  • Canada
• Europe (Type, Product Type, Application, Strength, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product Type, Application, Strength, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product Type, Application, Strength, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product Type, Application, Strength, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mallinckrodt Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
• Key Developments
• Air Liquide Healthcare (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VERO Biotech (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beyond Air, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SLE Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellerophon Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Biomedical (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NIOX Group plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BOC Healthcare (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nu-Med Plus Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perma Pure LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HALMA PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Matheson Tri-Gas Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Circassia Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Biomedical (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations